All News

Smile feedback opinion yes no good back opinion

What do our lupus patients think about treat-to-target?

d Md Yuzaiful Md Yusof, MRCP(UK), PhD

In SLE, two targets that are increasingly used are the DORIS 2021 Remission and the Lupus Low Disease Activity (LLDAS). T2T is more likely to be successful if the treating clinicians and the patients set the treatment goals together. What do our patients think about T2T and do they have any say/concern?

Read Article
monkeypox,lesions

MMWR: Monkeypox Outbreak in Nine States

d MMWR

CDC is tracking multiple reported U.S. monkeypox cases, and monitoring cases in persons in countries without endemic monkeypox and with no known travel links to an endemic area; current epidemiology suggests person-to-person community spread.

Read Article
RheumNow Podcast square

EULAR 2022 Top 10 Abstracts (6.10.2022)

d Jack Cush, MD

Dr. Jack Cush reviews the top abstracts from EULAR 2022  As chosen by me with the  aid of the RheumNow EULAR faculty.

Read Article
heart.jpg (keep)

CV risk factors not equal when considering magnitude of risk

d Janet Pope, MD, MPH, FRCPC

What can we learn from Oral Surveillance?



The Oral Surveillance trial has almost become a household word for rheumatologists.

Read Article
Watch: #EULAR2022 - Day 4 Faculty Panel Recap Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006. https://t.co/HomsEG9CdX https://t.co/LdMa2FUe76

Links:

Dr. John Cush RheumNow ( View Tweet)
WATCH: #EULAR2022 - Day 3 Faculty Panel Recap Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022. https://t.co/6Xdu3acGXN @Janetbirdope @AurelieRheumo @Yuz6Yusof https://t.co/juFkMtF5hS

Links:

Dr. John Cush RheumNow ( View Tweet)
#EULAR2022 - Day 2 Faculty Recap Panel Dr. Jack Cush, Dr. Robert Chao and Dr. Richard Conway discuss interesting abstracts and seminars from day 2 at EULAR 2022. https://t.co/aTVKYhggGD @doctorRBC @RichardPAConway https://t.co/kn3PkaFGSy

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: EULAR 2022 - Day 1 Faculty Recap Pane Drs. Jack Cush, Eric Dein and Kathryn Dao discuss highlights from day 1 at #EULAR2022 - Guidelines, Lupus, and more. https://t.co/WSOCQ8K38p https://t.co/0u28QHtxoJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Getting Real on PMR Dr. David Liew talks polymyalgia rheumatica and how our understanding has evolved over the years. #EULAR2022 https://t.co/j4LJPZFqzY https://t.co/ABAbm3axSG

Links:

Dr. John Cush RheumNow ( View Tweet)
Polymyalgia rheumatica immunological puzzle further illustrated Infiltrating macrophages expressing IL-6 and GM-CSF may drive the subacromial bursitis often seen in polymyalgia rheumatica, according to new research presented at #EULAR2022. https://t.co/Miab1eiHZ6 https://t.co/n9IjPwqG2t

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch this 4 minute video on Belimumab use in pregnancy featuring Dr. Kathryn Dao ( @KDAO2011 ) https://t.co/8uRUIVURHF https://t.co/lbYwHFFJit

Links:

Dr. John Cush RheumNow ( View Tweet)
Studies suggest that the IL-23/Th-17 axis is one of the key pathways involved in the pathogenesis of plaque psoriasis and psoriatic arthritis. Learn more here: https://t.co/oj00pk4dLT Sponsored by Janssen @JanssenUS https://t.co/4IhyX6sF7p

Links:

Dr. John Cush RheumNow ( View Tweet)
Miss this week's TNR? Watch the playback. https://t.co/LSlw939Vj2 https://t.co/K62afKWz95

Links:

Dr. John Cush RheumNow ( View Tweet)
Can we stop RA before it happens? Rheumatologists have long hoped and wondered whether the right type of early intervention could prevent RA occurring in at-risk individuals. https://t.co/vU4tRr7UJh https://t.co/cikU9pwaiT

Links:

Dr. John Cush RheumNow ( View Tweet)
Price of a newly launched drug increased from $2115 per year in 2008 to $180 007 per year in 2021. In 2008 only 9% of drug cost >$150k/yr; this rose to 47% by 2021. Greater increases seen w/ biologics, rare disease and nononcology drugs https://t.co/JaGzNqCxdF

Links:

Dr. John Cush RheumNow ( View Tweet)

Gout Undertreatment Persists Despite updated gout management guidelines from EULAR and BSR, treatment of gout is suboptimal with regard to the use of urate-lowering therapy (ULT) and normalizing serum uric acid (< 6.0 mg/dl) levels. https://t.co/qW7ZaXbnx3 https://t.co/ZBKIjuQp10

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: RA Potpourri on Day One EULAR 2022: Not An Ugly Duckling https://t.co/Lp25lP6ZZY https://t.co/wd5GCbaCLR

Links:

Dr. John Cush RheumNow ( View Tweet)
Video: Residual Pain in RA Dr. Maxime Dougados discusses OP0052 at #EULAR2022. https://t.co/gu1Svegss8 https://t.co/G1rRizG9gW

Links:

Dr. John Cush RheumNow ( View Tweet)
Review on reactive arthritis & COVID: 22 articles , 25 pts (14M:11F), age 45 yrs. Oligoarthritis was most common. Onset (COVID to arthritis) was 6-48 days. Steroids in 13, 2 w/ SSZ, Sxs improved 22/25, mean resolution was 16 +/- 57 days https://t.co/0YABcjz9Gk https://t.co/W5Vnn1NjkD

Links:

Dr. John Cush RheumNow ( View Tweet)
#LB0004 #EULAR2022 Positive Phase 2 results in #lupus! Deucravacitinib, a TYK2-inhibitor reported significantly more SRI-4 response rates in DEUC vs PBO. PBO: 34.4%; DEUC 3 mg BID:58.2%, DEUC 6 mg BID:49.5%, DEUC 12 mg QD:44.9%. No major safety. Will proceed to Phase 3 @RheumNow https://t.co/cZLv6bbHer
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
×